Home  /  Resource Library  /  A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naive Mantle Cell Lymphoma (MCL): First Report of the Investigator Initiated Australasian Leukaemia & Lymphoma Group NHL33 Wamm Trial

A Window Study of Acalabrutinib & Rituximab, Followed By Chemotherapy & Autograft (ASCT) in Fit Patients with Treatment Naive Mantle Cell Lymphoma (MCL): First Report of the Investigator Initiated Australasian Leukaemia & Lymphoma Group NHL33 Wamm Trial

ASH 2023